4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 112 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,160,414 | -31.9% | 1,033,811 | -3.4% | 1.46% | -13.8% |
| Q2 2023 | $19,334,900 | +5.1% | 1,070,000 | 0.0% | 1.69% | +11.6% |
| Q1 2023 | $18,393,300 | +31.5% | 1,070,000 | +69.8% | 1.52% | +39.8% |
| Q4 2022 | $13,992,300 | +260.9% | 630,000 | +13.4% | 1.08% | +230.5% |
| Q2 2022 | $3,877,000 | -53.8% | 555,455 | 0.0% | 0.33% | -13.0% |
| Q1 2022 | $8,398,000 | -31.1% | 555,455 | 0.0% | 0.38% | +9.9% |
| Q4 2021 | $12,187,000 | -59.5% | 555,455 | -50.2% | 0.34% | -54.2% |
| Q3 2021 | $30,084,000 | +12.0% | 1,115,455 | -0.0% | 0.75% | +9.8% |
| Q2 2021 | $26,863,000 | -37.8% | 1,115,555 | +12.1% | 0.68% | -47.0% |
| Q1 2021 | $43,178,000 | +33.5% | 995,354 | +27.5% | 1.29% | +34.1% |
| Q4 2020 | $32,354,000 | – | 780,555 | – | 0.96% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |